Table 2 demonstrates the clinical characteristics of the BA subgroups based on clinical outcome at six months post-operation. Subsequent analysis demonstrated the mean immunoreactive score of ATX protein expression in BA patients with poor outcome was significantly greater than in patients with good outcome (P = 0.03) (Fig. 3B). This evidence concerns the gene ENPP2 and breast angiosarcoma.